Patents by Inventor Glenn Dorin

Glenn Dorin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120040396
    Abstract: Methods and systems for purifying bio-organic compounds are described. In certain embodiments, the methods comprise the steps of (a) providing a composition or an emulsion comprising a surfactant, host cells, an aqueous medium and a bio-organic compound produced by the host cells, wherein the solubility of the surfactant in the aqueous medium decreases with increasing temperature and wherein the temperature of the composition or emulsion is at least about 1° C. below a phase inversion temperature of the composition or emulsion; (b) raising the temperature of the composition or emulsion to at least about 1° C. above the phase inversion temperature; and (c) performing a liquid/liquid separation of the composition to provide a crude bio-organic composition or emulsion.
    Type: Application
    Filed: August 5, 2011
    Publication date: February 16, 2012
    Applicant: Amyris, Inc.
    Inventors: Pinar Tabur, Glenn Dorin
  • Patent number: 7851433
    Abstract: Highly purified preparations of TFPI or TFPI analogs can be prepared using a method that generally involves the following steps: (1) expression of TFPI or TFPI analog in E. coli, (2) isolation of refractile bodies, (3) dissolution of the refractile bodies and refolding of the expressed TFPI or TFPI analog, (4) SP-Sepharose fast flow (FF) chromatography, (5) a first concentration and diafiltration step, (6) Q-Sepharose high (HP) performance chromatography, (7) butyl hydrophobic interaction chromatography (HIC), (8) SP-Sepharose HP chromatography, and (9) a second concentration/diafiltration step. Less than about 12% of the TFPI or TFPI analog molecules in such preparations are modified TFPI or TFPI analog species (i.e., oxidized, carbamylated, acetylated, deamidated, aggregated, or misfolded species).
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: December 14, 2010
    Assignees: Novartis Vaccines and Diagnostics, Inc., Pharmacia & Upjohn Company
    Inventors: David H. Reifsnyder, Duane Inlow, Glenn Dorin, Patricio T. Riquelme, Cynthia A. Cowgill, Douglas G. Bolesch, Mark E. Gustafson
  • Patent number: 7193042
    Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 20, 2007
    Assignees: Chiron Corporation, Cephalon, Inc.
    Inventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D. Kudrna, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
  • Patent number: 7071313
    Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: July 4, 2006
    Assignees: Cephalon, Inc., Chiron Corporation
    Inventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D Kudrna, Asuman G. Ozturk, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
  • Publication number: 20060128947
    Abstract: Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 15, 2006
    Applicants: Chiron Corporation, G. D. Searle & Co.
    Inventors: Glenn Dorin, Bo Arve, Gregory Pattison, Robert Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan Rana, Maninder Hora, Hassan Madani, Michael Tsang, Mark Gustafson, Gary Bild, Gary Johnson
  • Publication number: 20050037475
    Abstract: Highly purified preparations of TFPI or TFPI analogs can be prepared using a method that generally involves the following steps: (1) expression of TFPI or TFPI analog in E. coli, (2) isolation of refractile bodies, (3) dissolution of the refractile bodies and refolding of the expressed TFPI or TFPI analog, (4) SP-Sepharose fast flow (FF) chromatography, (5) a first concentration and diafiltration step, (6) Q-Sepharose high (HP) performance chromatography, (7) butyl hydrophobic interaction chromatography (HIC), (8) SP-Sepharose HP chromatography, and (9) a second concentration/diafiltration step. Less than about 12% of the TFPI or TFPI analog molecules in such preparations are modified TFPI or TFPI analog species (i.e., oxidized, carbamylated, acetylated, deamidated, aggregated, or misfolded species).
    Type: Application
    Filed: January 8, 2004
    Publication date: February 17, 2005
    Applicants: Chiron Corporation, Pharmacia & Upjohn Company
    Inventors: David Reifsnyder, Duane Inlow, Glenn Dorin, Patricio Riquelme, Cynthia Cowgill, Douglas Bolesch, Mark Gustafson
  • Patent number: 6756484
    Abstract: Disclosed is an improved process for obtaining purified, monomeric, intact, correctly-folded insulin-like growth factor-I (also known as somatomedin-C). The improvements, consisting primarily of the addition of an IGF-I unfolding/refolding step and the substitution of a reverse phase chromatography step for a gel filtration chromatography step result in a three-fold increase in final yield. The process includes the following steps, in order: first cation exchange, unfolding/refolding, hydrophobic interaction chromatography, second cation exchange, and reverse phase chromatography.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: June 29, 2004
    Assignees: Cephalon, Inc., Chiron Corporation
    Inventors: Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka, Cynthia Cowgill, Luis G. Juarbe-Osorio, Patricio Riquelme, Glenn Dorin
  • Patent number: 6117983
    Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: September 12, 2000
    Assignee: Chiron Corporation
    Inventors: Cynthia Cowgill, Louis Juarbe, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D. Kudrna, Ausman G. Otzurk
  • Patent number: 6033875
    Abstract: The present invention relates to a method of making a recombinant protein in high yields by adding alkali to a cell culture that is capable of producing recombinant protein. The recombinant protein can be any protein that is suitable to be made by recombinant techniques, such as IGF.
    Type: Grant
    Filed: January 24, 1997
    Date of Patent: March 7, 2000
    Assignee: Chiron Corporation
    Inventors: Christopher M. Bussineau, Glenn Dorin, Robert D. Kudrna
  • Patent number: 5814485
    Abstract: Methods for the production of interferon-.beta. polypeptides by bacterial cells, by culturing cells capable of producing IFN-.beta. polypeptide under conditions that induce increased production of IFN-.beta. polypeptide. Such conditions include, for example, low potassium cation concentration and/or very low sodium cation concentration and/or specific pH ranges.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 29, 1998
    Assignee: Chiron Corporation
    Inventors: Glenn Dorin, Patrick J. McAlary, Kathleen M. Wong
  • Patent number: 5466781
    Abstract: A process is described for producing M-CSF from bacteria. It includes: fermentation of bacteria containing M-CSF DNA; harvest of the fractions that contain the M-CSF protein (refractile bodies); primary recovery of the protein; solubilization and denaturation of refractile bodies; M-CSF refolding; purification by column chromatography and other methods; and formulation of the properly refolded M-CSF. This method is advantageous over prior methods in terms of yield and purity.
    Type: Grant
    Filed: March 8, 1993
    Date of Patent: November 14, 1995
    Assignee: Chiron Therapeutics
    Inventors: Glenn Dorin, David R. Gray, Byeong S. Chang, Cynthia A. Cowgill, Robert J. Milley
  • Patent number: 5248769
    Abstract: A refractile material containing a heterologous protein is recovered from a host microorganism cell culture transformed to produce the protein. One recovery process involves first reducing the ionic strength of the culture medium prior to disruption to a level effective in preventing reaggregation of cellular debris with refractile material after disruption, disrupting the desalted culture, optionally adding material to the disruptate to create a density or viscosity gradient and separating the refractile material from the cellular debris by high-speed centrifugation. Preferably the salt removal step is carried out by diafiltration and the heterologous protein comprises recombinant M-CSF, IL-2 or IFN-.beta..
    Type: Grant
    Filed: November 25, 1991
    Date of Patent: September 28, 1993
    Assignee: Cetus Oncology Corporation
    Inventor: Glenn Dorin
  • Patent number: 4894334
    Abstract: A method for improving the yield of heterologous protein such as ricin A toxin, produced by recombinant bacteria by supplementing the nutrient medium in which the bacteria are grown with an ethanol and/or amino acid mixture during the terminal phase of the cultivation. Also disclosed is a method for improving the yield of heterologous proteins under the control of the PL promoter.
    Type: Grant
    Filed: April 6, 1987
    Date of Patent: January 16, 1990
    Assignee: Cetus Corporation
    Inventors: Arie Ben-Bassat, Glenn Dorin, Keith Bauer
  • Patent number: 4894439
    Abstract: A process is disclosed for the purification of recombinantly produced biologically active proteins in which a solution containing a mixture of materials, including the biologically active protein, is passed through a continuous porous hydrophobic membrane, and the fraction enriched in the biologically active protein is recovered. Hydrophobic proteins such as TNF and recombinant ricin toxin A chain may be purified according to the process. Conditions for enhanced recovery of purified TNF using the process are disclosed. A highly purified TNF comprising 95% or greater TNF as determined by SDS-PAGE analysis, with an endotoxin content of less than 0.1 ng/mg TNF which is substantially free of pyrogens by the USP rabbit pyrogen test at a dosage range of 1.0 to 2.4.times.10.sup.5 U/kg, is obtained.
    Type: Grant
    Filed: May 22, 1986
    Date of Patent: January 16, 1990
    Assignee: Cetus Corporation
    Inventors: Glenn Dorin, Wolfgang H. Hanisch, James W. Thomson, Sidney N. Wolfe, Leo S. Lin
  • Patent number: 4748234
    Abstract: A refractile material containing a heterologous protein is recovered from a host microorganism cell culture transformed to produce the protein. One recovery process involves disrupting the cell wall and membrane of the host cell, removing greater than 99% by weight of the salts from the disruptate, redisrupting the desalted disruptate, adding a material to the disruptate to create a density or viscosity gradient in the liquid within the disruptate, and separating the refractile material from the cellular debris by high-speed centrifugation. Another version of such a recovery process comprises the further steps of solubilizing the refractile material under reducing conditions, organically extracting the solubilized refractile material, and isolating said refractile material from the extractant.Preferably the protein is recombinant IL-2 or IFN-.beta. and the salt removal step is carried out by diafiltration.
    Type: Grant
    Filed: March 25, 1986
    Date of Patent: May 31, 1988
    Assignee: Cetus Corporation
    Inventors: Glenn Dorin, Wolfgang H. Hanisch, Leo S. Lin
  • Patent number: 4656132
    Abstract: A method for improving the yield of heterologous protein such as IFN-.alpha., IFN-.beta., and IL-2, produced by recombinant bacteria by supplementing the nutrient medium in which the bacteria are grown with a water soluble alcohol and/or amino acid mixture during the terminal phase of the cultivation.
    Type: Grant
    Filed: March 28, 1984
    Date of Patent: April 7, 1987
    Assignee: Cetus Corporation
    Inventors: Arie Ben-Bassat, Glenn Dorin, Keith Bauer, Leo Lin